Objective: To compare the efficacy, global tolerability and blood pressure effects of tamsulosin (0.4 mg once daily) in subgroups of patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO). Methods: Data from two open-label, observational studies (Study I: 9,507 patients treated for 4 weeks, Study II: 9,858 patients treated for 12 weeks) were analyzed to compare efficacy, global tolerability and effects on blood pressure in subgroups of patients. Results: The efficacy of tamsulosin was largely unaffected by age or previous phytotherapy; in patients with severe symptoms, the efficacy was at least as large as in those with mild or moderate symptoms. More than 90% of patients reported a good or very good tolerability; in a multivariate analysis, this was slightly reduced in patients with concomitant disease but not affected by antihypertensive co-medication or baseline blood pressure. In patients without co-morbidity or co-medication, the tamsulosin-induced blood pressure reductions were similar to those previously reported for placebo treatment; mean additional blood pressure reductions in patients with concomitant disease or medication was not more than 2 mm Hg. Patients who had previously been treated with β-sitosterol, other plant extracts or finasteride reported tamsulosin to be more effective than their previous treatment. Patients who had previously received β-sitosterol or other plant extracts rated the global tolerability of tamsulosin to be similar to that of their previous treatment, while those who had previously received finasteride or other α1-adrenoceptor antagonists rated the global tolerability of tamsulosin to be significantly better than that of their previous treatment. Conclusions: We conclude that tamsulosin is efficacious in all types of patients with LUTS suggestive of BPO. It is globally well tolerated and has marginal effects on blood pressure, including the vast majority of patients with cardiovascular comorbidity, diabetes or on antihypertensive comedication.

Keywords:
Tamsulosin, Lower urinary tract symptoms, Diabetes, Hypertension
1.
Berges RR, Windeler J, Trampisch HJ, Senge T: Randomised, double-blind clinical trial of β-sitosterol in patients with benign prostatic hyperplasia. Lancet 1995;354:1529–1532.
2.
Lowe FC, Ku JC: Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 1996;48:12–18.
3.
Plosker GL, Brogden RN: Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 1996;9:379–395.
4.
Rittmaster RS: Finasteride. N Engl J Med 1994;330:120–125.
5.
Boyle P, Gould AL, Roehrborn CG: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48:398–405.
6.
Chapple CR: Selective α1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 1996;29:129–144.
7.
Eri LM, Tveter KJ: α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol 1995;154:923–934.
8.
Andersson K-E, Lepor H, Wyllie MG: Prostatic α1-adrenoceptors and uroselectivity. Prostate 1997;30:202–215.
9.
Michel MC, Mehlburger L, Bressel H-U, Schumacher H, Schäfers RF, Goepel M: Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does comorbidity alter tolerability? J Urol (in press).
10.
Chapple CR, Wyndaele JJ, Nordling J, Boeminghaus F, Ypma AFGVM, Abrams P: Tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). Eur Urol 1996;29:155–167.
11.
Lepor H: Phase III multicenter, placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892–900.
12.
Roehrborn CG, Siegel RL: Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. Urology 1996;48:406–415.
13.
Lee E, Lee C: Clinical comparison of selective and non-selective α1A-adrenoceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol 1997;80:606–611.
14.
Lukacs B, Leplege A, Thibault P, Jardin A: Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996;48:731–740.
15.
de Planque BA: A double-blind comparative study of doxazosin and prazosin when administered with β-blockers or diuretics. Am Heart J 1991;121:304–311.
16.
Englert RG, Barlage U: The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by β-blockers. Am Heart J 1991;121:311–316.
17.
Lindner UK, von Manteuffel G-E, Stafunsky M: The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine. Am Heart J 1988;116:1814–1820.
18.
Englert RG, Mauersberger H: A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy. Am Heart J 1988;116:1826–1832.
19.
Brawer MK, Adams G, Epstein H: Terazosin in the treatment of benign prostatic hyperplasia. Arch Fam Med 1993;2:929–935.
20.
Fawzy A, Braun K, Lewis GP, Gaffney M, Ice K, Dias N: Doxazosin in the treatment of benign prostatic hyerplasia in normotensive patients: a multicenter study. J Urol 1995;154:105–109.
21.
Kirby RS: Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995;46:182–186.
22.
Oparil S: Antihypertensive therapy – efficacy and quality of life. N Engl J Med 1993;928:959–961.
23.
van Zwieten PA: α-Adrenoceptor blocking agents in the treatment of hypertension; in Laragh JH, Brenner BM (eds): Hypertension: Pathophysiology, Diagnosis and Management. New York, Raven Press, 1995, pp 2917–2935.
24.
Carraro J-C, Raynaud J-P, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231–240.
25.
Sökeland J, Albrecht J: Kombination aus Sabal- und Urticaextrakt vs. Finasterid bei BPH (Stad. I bis II nach Alken). Vergleich der therapeutischen Wirksamkeit in einer einjährigen Doppelblindstudie. Urologe A 1997;36:327–333.
26.
Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533–539.
27.
Adriazola-Semino M, Lozano-Ortega JL, Garcia-Cobo E, Tejeda-Banez E, Romero-Rodriguez F: Tratamiento sintomatico de la hipertrofia benigna de prostata. Estudio comparativo entre prazosin y Serenoa repens. Arch Esp Urol 1992;45:211–213.
28.
Grasso M, Montesano A, Buonaguldi A, Castelli M, Lania C, Rigatti P, Rocco F, Cesana BM, Borghi C: Comparative effects of alfuzosin versus serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch Esp Urol 1995;48:97–104.
29.
Buzelin JM, Fonteyne E, Kontturi MJ, Witjes WPJ, Khan A: Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms sugestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 1997;80:597–605.
30.
Chapple CR, Carter P, Christmas TJ, Kirby RS, Bryan J, Milroy EJG, Abrams P: A three month double-blind study of doxazosin as treatment for benign prostatic bladder outlet obstruction. Br J Urol 1994;74:50–56.
31.
Roehrborn CG, Oesterling JE, Auerbach S, Kaplan SA, Lloyd LK, Milam DF, Padley RJ: The Hytrin community assessment trial study: a one-year study of terazosin versus placebo in the treatment of patients with symptomatic benign prostatic hyerplasia (BPH). Urology 1996;47:159–168.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.